Genetic variant of cytomegalovirus (cmv)
OwnerCecilia Nauclérinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to a genetic variant of CMV, said genetic variant lacking intron 2 of the IE region of CMV (CMV IEΔi2) The present invention also relates to various uses of this genetic variant as well as RNA splice variants transcribed therefrom, and proteins expressed from the RNA splice variants, such as in the diagnosis of a CMV related cancer disease, and identification of individuals at risk of developing cancer or risk of transferring the CMV IEΔi2 virus with a human sample and prevention and treatment through targeting of unique CMV IE proteins for immunotherapy and vaccination.
Claims2
A genetic variant of Cytomegalovirus (CMV), said genetic variant being characterized by lacking intron 2 (SEQ ID:17) of the Immediate Early (IE) gene of the CMV genome (CMV IEΔi2).
2-32. (canceled)
Dependencies are inferred from the claim text.